In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|December 8, 2020
Samsung Biologics Launches Virtual Showroom
Author(s)BioPharm International Editors
The virtual showroom will provide real-time construction updates, various specs, and services that its new super plant, Plant 4, will offer upon completion.
Advertisement
Samsung Biologics announced on Dec. 4, 2020 that it is launching a virtual showroom to showcase key features of its new super plant, Plant 4.
The virtual showroom will provide real-time construction updates, various specs, and services that the new plant will offer upon completion, while also allowing the company to connect with clients interested in the plant’s progression, a company press release said. Construction started on the new plant in
“Our new super plant and our virtual showroom are a direct response to an accelerated demand in the industry for both traditional and digitally enabled services. By leveraging the latest innovation, Plant 4 will provide easy and secure access to manufacturing and quality information whenever customers require it and deliver the highest levels of client satisfaction and regulatory compliance,” said Dr. Tae Han Kim, CEO of Samsung Biologics, in the press release. “Our Plant 4 Virtual Showroom also exemplifies Samsung Biologics’ latest efforts to lead the industry in the digital revolution for enhanced connectivity and agility in responding to our clients, partners, and shareholders.”
Source: Samsung
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5